Home » Headlines » Currently Reading:

Morning Headlines 8/31/22

August 30, 2022 Headlines No Comments

Software Firm Everbridge Is Exploring Potential Sale

Critical event management technology company Everbridge reportedly considers putting itself up for sale, causing its share price to jump in after-hours trading.

Healee lands $2M to grow customizable telehealth solution in the U.S.

White-label digital health technology startup Healee raises $2 million in a seed funding round led by Nina Capital.

Genesis Growth Tech (GGAA) to Combine with Biolog-id in $312M Deal

Medical product RFID tracking vendor Biolog-ID announces plans to go public in a $312 million SPAC merger.

$1 billion digital-health startup Wheel cut 17% of its staff in August. Read the CEO’s full memo announcing the layoffs.

White-label telemedicine and staffing company Wheel reportedly lays off 17% of its staff.



HIStalk Featured Sponsors

     

Founding Sponsors


 

Platinum Sponsors


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gold Sponsors


 

 

 

 

 

 

 

 

Text Ads


HIStalk Text Ads
Big audience, low price.
Seven lines on the
most talked about site
in the industry. Easy -
your ad starts in hours
and is seen by thousands
of visitors each day.

more ...

Advertise here
What ways have you recently used to reduce the time you spend on unproductive meetings?

RECENT COMMENTS

  1. The Advisory Opinion on that page states "The Veterans Health Administration (VHA) is designated a health plan... VHA's treatment activities…

  2. It's nice to see someone describing AI as anything but marvelous! Shiny objects take polishing to really glow.

  3. Actually if you have Cerner aka Oracle, you probably don't want to auto delete messages. When you do so, they…

  4. Epic & Agentic AI: This is a well-reasoned perspective. However, given Epic's historical approach to technological innovation, call me a…

RSS Webinars

  • An error has occurred, which probably means the feed is down. Try again later.